Cancer vaccines with emphasis on a viral oncolysate melanoma vaccine

Acta Microbiologica et Immunologica Hungarica

Volumn 46, Issue 1, 1999, Pages 1-20

  Horvath, Joseph C ^a,b   Horak, Andrea ^a,b   Sinkovics, Joseph G ^a,b   Pritchard, Mary ^a,b   Pendleton, Stacia ^a,b   Horvath, Elizabeth ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b ST JOSEPH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOBACTERIUM BOVIS BCG;

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; POLYVALENT MELANOMA CELL VACCINE; VIRUS VACCINE;

ANIMAL; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; MELANOMA; METHODOLOGY; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CLINICAL TRIALS; HUMANS; MELANOMA; VIRAL VACCINES;

EID: 0032610849     PISSN: 12178950     EISSN: None     Source Type: Journal    
DOI: 10.1556/amicr.46.1999.1.1     Document Type: Article

References (113)

1. Ferrone, S., Marincola, F.M.: Loss of HLA class I antigens by melanoma cells: molecular mechanism, functional significance and clinical relevance. Immunol Today 16, 487 (1995).
2. Kiessling, R., Kono, K., Petersson, M., Wasserman, K.: Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Semin Immunopathol 18, 227 (1996).
3. Mitchell, M.S., Kan-Mitchell, J., Kempf, R.A., Harel, W., Shau, H., Lind, S.: Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48, 5883 (1988).
4. Pomer, S., Thiele, R., Stahler, G., Drehmer, I., Lohrke, H., Schirrmacher, V.: Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization. Urologe A 34, 215 (1995).
5. Bronte, V., Tsung, K., Rao, J.B., Chen, P.W., Wang, M., Rosenberg, S.A., Restifo, N.P.: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 154, 5282 (1995).
6. Storkus, W.J., Zeh, H.J., Maeurer, M.J., Salter, R.D., Lotze, M.T.: Identification of human melanoma peptides recognized by Class I restricted tumor infiltrating lymphocytes. J Immunol 151, 3719 (1993).
7. Bernhardt, H., Jager, E., Maeurer, M.J., Meyer zum Buschenfelds, K.H., Knuth, A.: Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes. Tissue Antigens 48, 22 (1996).
8. Robbins, P.F., Kawakami, Y.: Human tumor antigens recognized by T cells. Curr Opinion in Immunol 8, 628 (1996).
9. Lupetti, R., Pisarra, P., Verrecchia, A., Farina, C., Nicolini, G., Anichini, A., Bordignon, C., Sensi, M., Parmiani, G., Traversari, C.: Translation of a retained intron in tyrosinase-related-protein (TRP)2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanoma lineage. J Exp Med 188, 1005 (1998).
10. Vierboom, M.P., Nijman, H.W., Offringa, R., van der Voort, E.I., van Hall, T., van der Broek, L., Fleuren, G.J., Kenemans, P., Kast, W.M., Melief, C.J.: Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186, 695 (1997).
11. Van Pel, A., van der Bruggen, P., Coulie, P.G., Brichard, V.G., Lethe, B., van den Eynde, B., Uyttenhove, C., Renauld, J.C., Boon, T.: Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunology Rev 145, 229 (1995).
12. Rosenberg, S.A., Kawakami, Y., Robbins, P.F., Wang, R.F.: Identification of genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res 70, 145 (1996).
13. Matsui, K., Boniface, J.J., Reay, P.A., Schild, H., Fazekas de St. Groth, B., Davis, M.M.: Low affinity interaction of peptide-MHC complexes with T-cell receptors. Science 254, 1788 (1991).
14. Couderc, B., Zitvogel, L., Douin-Echinard, V., Gjennane, L., Tahara, H., Favre, G., Lotze, M.T., Robbins, P.D.: Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD 154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther 5, 163 (1998).
15. Ohmori, T., Okada, K., Arita, N., Watanabe, Y., Miyazaki, T., Taberi, R.: Characteristics of MHC antigen expression and tumor-infiltrating mononuclear cells in renal cell adenomas and carcinomas. Histol Histopathol 10, 789 (1995).
16. Cordon-Cardo, C., Fuks, Z., Drobnjak, M., Moreno, C., Eisenbach, L., Feldman, M.: Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51, 6372 (1991).
17. Marincola, F.M., Shamamian, P., Alexander, R.B., Gnarra, J.R., Turetskaya, R.L., Nedospasov, S.A., Simonis, T.B., Taubenberger, J.K., Yannelli, J., Mixon, A., Restifo, N.P., Herlyn, M., Rosenberg, S.A.: Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 153, 1225 (1994).
18. Natali, P.G., Nicotra, M.R., Bigotti, A., Venturo, I., Marcenaro, L., Giacomini, P., Russo, C.: Selective changes in expression of HLA Class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA 86, 6719 (1989).
19. Sinkovics, J., Horvath, J., Horak, A.: Lymphocytes cytotoxic to human tumor cells. In Rao, R.S., Deo, M.G., Sanghvi, L.D., Mittra, I. (eds): Proceedings of the XVI International Cancer Congress. Bologna, Italy, 1994. pp. 93-102
20. Luboldt, H.J., Kubens, B.S., Rubben, H., Grosse-Wilde, H.: Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 56, 826 (1996).
21. Restifo, N.R., Marincola, F.M., Kawakami, Y., Taubenberger, J., Yannelli, J.R., Rosenberg, S.A.: Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. JNCI 88, 100 (1996).
22. Maeurer, M.J., Gollin, S.M., Storkus, W.J., Swaney, W., Karbach, J., Martin, D., Castelli, C., Salter, R., Knuth, A., Lotze, M.T.: Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res. 2, 641 (1996).
23. Everson, M.P., Lemak, D.G., McDuffie, D.S., Koopman, W.J., McGhee, J.R., Begley, W.W.: Dendritic cells from Peyer's patch and spleen induce different T helper cell responses. J. Interferon Cytokine Res 18, 103 (1998).
24. Michell, M.S., Harel, W., Kan-Mitchell, J., LeMay, L.G., Goedegebuure, P., Hang, X.Q., Hoffman, F., Groshen, S.: Active specific immunotherapy of melanoma with allogeneic cell lysates. Rational, results, and possible mechanisms of action. Ann N Y Acad Sci 690, 153 (1993).
25. Mitchell, M.S., Jakowitz, J., Harel, W., Dean, G., Stevenson, L., Boswell, W.D., Groshen, S.: Increased effectiveness of interferon alpha-2B following active specific immunotherapy for melanoma. J Clin Oncol 12, 402 (1994).
26. Mitchell, M.S., Liggett, P.E., Kan-Mitcell, J., Murphree, A.L., Dean, G., Spears, L., Walonker, F.: Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine. J Clin Oncol 12, 396 (1994).
27. von Eschen, K.B., Mitchell, M.S.: Phase III trial of melacine melanoma therracine versus combination chemotherapy in the treatment of stage IV melanoma. Oral abstracts of the 4th World Conference on Melanoma. Melanoma Res 7, S51 (1997).
28. Sinkovics, J.G., Plager, C., McMurray, M.J.: Chemoimmunotherapy: basic principles and clinical examples. Adv Med Oncol. Research and Education (M. Moore, ed.) Oxford, New York: Pergamon Press 6, 121 (1979).
29. Morton, D.L., Foshag, L.J., Hoon, D.S.B., Nizze, J.A., Wanek, L.A., Chang, C., Davtyan, D.G., Gupta, R.K., Elashoff, R., Irie, R.F.: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216, 463 (1992).
30. Berd, D., Maguire, H.C., Mastrangelo, M.J.: Treatment of human melanoma with a hapten-modified autologous vaccine. Ann NY Acad Sci 690, 147 (1993).
31. Berd, D., Maguire, H.C., Schuchter, L.M., Hamilton, R., Hauck, W.W., Sato, T., Mastrangelo, M.J.: Autologus hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15, 2359 (1997).
32. Sensi, M., Farina, C., Maccalli, C., Anichini, A., Berd, D., Parmiani, G.: Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination. J Immunother 21, 198 (1998).
33. Kageshita, T., Hirai, S., Ono, T., Ferrone, S.: Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic MAb MK2-23. Immunohistochemical analysis of the reactivity of anti-idiotypic MAb with surgically removed melanoma lesions. Int J Cancer 6, 334 (1995).
34. Sharma, S., Miller, P.W., Stolina, M., Zhu, L., Huang, M., Paul, R.W., Dubinett, S.M.: Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells. Gene Ther 4, 1361 (1997).
35. Jaffe, E.M., Dranoff, G., Cohen, L.K.L., Hauda, K.M., Clif, S., Marshall, F.F., Mulligan, R.C., Pardoll, D.M.: High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 53, 2221 (1993).
36. Schweighoffer, T., Berger, M., Buschle, M., Schmidt, W., Birnstiel, M.L.: Adenovirus-enhanced receptor-mediated transferrinfection for the generation of tumor vaccines. Cytokines Mol Ther 2, 185 (1996).
37. Abdel-Wahab, Z., Weltz, C., Hester, D., Pickett, N., Vervaert, C., Barber, J.R., Jolly, D, Seigler, H.F.: A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer 80, 401 (1997).
38. Elder, E.M., Lotze, M.T., Whiteside, T.L.: Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biological therapy of patients with cancer. Hum Gene Ther 7, 479 (1996).
39. McArthur, J.G., Mulligan, R.C.: Induction of protective anti-tumor immunity by gene-modified dendritic cells. J Immunother 21, 44 (1998).
40. Tuting, T., DeLeo, A.B., Lotze, M.T., Storkus, W.J.: Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 27, 2702 (1997).
41. Miller, K., Abeles, G., Oratz, R., Zeleniuch-Jacquotte, A., Cui, J., Roses, D.F., Harris, M.N., Bystrin, J-C.: Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75, 495 (1995).
42. Bystryn, J-C., Henn, M., Li, J., Shroba, S.: Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res 52, 5948 (1992).
43. Chu, J.W., Sharom, F.J: Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors. Immunol 79, 10 (1993).
44. Helling, F., Zhang, S., Shang, A., Adluri, S., Calves, M., Koganty, R., Longenecker, B.M., Yao, T.J., Oettgen, H.F., Livingston, P.O.: GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55, 2785 (1995).
45. Ritter, G., Ritter-Boosfeld, E., Adluri, R., Calves, M., Ren, S., Yu, R.R., Oettgen, H.F., Old, L.J., Livingston, P.O.: Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliozides in patients with malignant melanoma. Int J Cancer 62, 668 (1995).
46. Livingston, P.O., Zhang, S., Adluri, S., Yao, T.J., Graeber, L., Ragupathi, G., Helling, F., Fleisher, M.: Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Cancer Immunol Immunother 43, 324 (1997).
47. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Dudley, M.E., Schwarz, S.L., Spiess, P.J., Wunderlich, J.R., Parkhurst, M.R., Kawakami, Y., Seipp, C.A., Einhorn, J.H., White, D.E.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4, 321 (1998).
48. Gong, J., Chen, D., Kishiwaba, M., Kufe, D.: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Medicine 3, 558 (1997).
49. Nair, S.K., Snyder, D., Rouse, B.T, Gilboa, E.: Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 70, 706 (1997).
50. Nestle, O.F., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., Schadendorf, D.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine 4, 328 (1998).
51. Earl, P.L., Moss, B., Morrison, R.P., Wehrly, J., Nishio, J., Chesebro, B.: T-lymphocyte priming and protection against Friend leukemia by vaccina-retrovirus env gene recombinant. Science 234, 728 (1986).
52. Lathe, R., Kieny, M.P., Gerlinger, P., Clertant, P., Guizan, I., Cuzin, F., Chambon, P.: Tumour prevention and rejection with recombinant vaccinia. Nature (London) 326, 878 (1987).
53. Gu, S., Huang, T., Miao, Y., Ruan, L., Zhao, Y., Han, C., Xiao, Y., Zhu, J., Wolf, H.: A preliminary study on the Immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing EpsteinBarr virus membrane antigen. Chin Med Sci J 6, 241 (1991).
54. Hu, Sh-L., Plowman, G.D., Sridhar, P., Stevenson, U.S., Brown, J.P., Estin, C.D.: Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97. J Virol 62, 176 (1988).
55. Mandl, S., Sigal, L.J., Rock, K.L., Andino, R.: Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect against lethal challenge with malignant melanoma cells expressing a model antigen PNAS 95, 8216 (1998).
56. Roth, J., Dittmer, D., Rea, D., Tartaglia, J., Paoletti, E., Levine, A.J.: p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. PNAS 93, 4781 (1996).
57. Fong, I., Ruegg, C.L., Brockstedt, D., Engelman, E.G., Laus, R.: Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 159, 3113 (1997).
58. Boursnell, M.E., Rutherford, E., Hickling, J.K., Rollinson, E.A., Munro, A.J., Rolley, N., McLean, C.S., Borysiewicz, L.K., Vousden, K., Inglis, S.C.: Construction and characterization of a recombinant vaccinia virus expressing papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14, 1485 (1996).
59. Borysiewicz, L.K., Fiander, A., Nimoako, M., Wilkinson, G.W., Westmoreland, D., Evans, A.S., Adams, M., Stacey, S.N., Boursnell, M.E., Rutherford, E., Hickling, J.K., Inglish, S.C.: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347, 1523 (1996).
60. Hariharan, K., Braslawsky, G., Barnett, R.S., Berquist, L.G., Huynh, T., Hanna, N., Black, A.: Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int J Oncol 12, 1229 (1998).
61. Hodge, J.W., Schlom, J., Donohue, S.J., Tomaszewski, J.E., Wheeler, C.W., Levine, B.S., Gritz, L., Panicali, D., Kantor, J.A.: A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 63, 231 (1995).
62. Irvin, K.R., Chamberlain, R.S., Shulman, E.P., Surman, D.R., Rosenberg, S.A., Restifo, N.P.: Enhancing efficacy of recombinant anticancer vaccines with prime/boost regiment that use two different vectors. J Natl Cancer Inst 89, 1595 (1997).
63. Donnelly, J.J., Ulmer, J.B., Shiver, J.W., Liu, M.A.: DNA vaccines. Ann Review Immunol 15, 617 (1997).
64. Mahvi, D.M., Sheehy, M.J., Yang, N.S.: DNA cancer vaccines: a gene gun approach. Immunol Cell Biol 75, 456 (1997).
65. Stopeck, A.T., Hersh, E., Akporiaye, E.T., Harris, D.T., Grogan, T., Unger, E., Warneke, J., Schluter, S.F., Stahl, S.: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 15, 341 (1997).
66. Waddill, W., Wright, W., Unger, E., Stopeck, A.T., Akporiaye, E., Harris, D., Grogan, T., Schluter, S., Hersh, E., Stahl, S.: Human gene therapy for melanoma: CT guided interstitial injection. AJR Am J Roentgenol 169, 63 (1997).
67. Lindenmann, J., Klein, P.: Immunological aspects of viral oncolysis. Recent Results Cancer Res 9, 1 (1967).
68. Koprowski, H., Love, R., Koprowska, I.: Viruses and tumor growth. Tex Rep Biol Med 15, 111 (1957).
69. Sinkovics, J.G., Thota, H., Kay, H.D., Loh, K.K., Williams, D.E., Howe, C.D., Schullenberger, C.C.: Intensification of immune reactions by immunotherapy. Attempts at measuring sarcoma-specific reactions in vitro. In: Crispen, R.G. (ed.): Neoplasm Immunity: Theory and Application. Evanston. University of Illinois Press, 1974. pp. 137-152
70. Sinkovics, JG, Plager, C, Romero, JJ.: Immunology and immunotherapy of patients with sarcomas In Crispen, R. (ed.): 1977 Chicago Symposium: Immunotherapy of Solid Tumors. Franklin Institute Press. Philadelphia PA. 1977. pp. 211-219
71. Sinkovics, J.G., Plager, C., McMurray, M., Papadopoulos, N.E., Waldinger, R., Combs, S., Romero, J.J., Romsdahl, M.M.: Adjuvant chemo immunotherapy for malignant melanoma. In Crispen, R. (ed.): Neoplasm Immunity: Experimental and Clinical. Elsevier North Holland, New York, Amsterdam. 1980. pp. 481-519
72. Sinkovics, J.G., Papadopoulos, N.E., Plager, C.: Viral oncolysates for the immunotherapy of human tumors. In Yohn, D.S., Blakeslee, J.J. (eds): Proceedings of the 10th International Symposium for Comparative Research on Leukemia and Related Diseases. Elsevier BioMed, New York, Amsterdam. 1981. pp. 613-615
73. Sinkovics, J.G.: Immunotherapy with viral oncolysates for sarcoma. JAMA 237, 869 (1977).
74. Sinkovics, J.G.: Complete remissions lasting over three years in adult patients treated for metastatic sarcoma. In Crispen, R. (ed.): Tumor Progression. Elsevier, Amsterdam, New York. 1980. pp. 315-331
75. Cassel, W.A., Weidenheim, K.M., Campbell, W.G., Murray, D.R.: Malignant melanoma. Inflammatory mononuclear cell infiltrates in cerebral metastases during concurrent therapy with viral oncolysates. Cancer 57, 1302 (1986).
76. Cassel, W.A., Murray, D.R.: A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 9, 169 (1993).
77. Wallack, M.K., Bash, J.A., Leftheriotis, E., Seigler, H., Bland, K., Wanebo, H., Balch, C., Bartolucci, A.A.: Positive relationship of clinical and serological responses to vaccinia melanoma oncolysates. Arch Surg 122, 1460 (1987).
78. Wallack, M.K., Sivanandham, M., Balch, C.M., Urist, M.M., Bland, K.I., Murray, D., Robinson, W.A., Flaherty, L., Richards, J.M., Bartolucci, A.A., Rosen, L.: Surgical adjuvant active specific immunotherapy for patients with Stage III melanoma: The final analysis of data from a Phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187, 69 (1998).
79. Kirchner, H.H., Anton, P., Atzpodien, J.: Adjuvant treatment of locally advanced renal cell cancer with autologous virus-modified tumor vaccines. World J Urol 13, 171 (1995).
80. Schirrmacher, V., Ahlert, T., Pröbstle, T., Steiner, H.-H., Herold-Mende, C., Gerhards, R., Hagmüller, E.: Immunization with virus-modified tumor cells. Sem Oncol 25, 677 (1998).
81. Möbus, V., Horn, S., Stöck, M, Schirrmacher, V.: Tumor cell vaccination for gynecological tumors. Hybridoma 12, 543 (1993).
82. Schlag, P., Manasterski, M., Gerneth, T., Hohenberger, P., Dueck, M., Herfarth, C., Liebrich, M., Schirrmacher, V.: Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol. Immunother 35, 325 (1992).
83. Freedman, R.S., Kouttab, N.M., Bowen, J.M., Edwards, C.L., Katz, R.L.: Lymphokine activity in malignant effusions after intracavity viral oncolysate. Lymphokine Res 8, 115 (1989).
84. Ioannides, C.G., Freedman, R.S., Patenia, R., Bowen, J.M., Ward, N.E., O'Brian, C.A.: Immunological effects of tumor vaccines: III Influenza virus oncolysates inhibit the TPA induced activation of peripheral blood mononuclear cells. In Vivo 5, 1 (1991).
85. Ioannides, C.G., Freedman, S.R.: T cell responses to ovarian tumor vaccines: identification and significance for future immunotherapy. Intern Rev Immunol 7, 349 (1991).
86. Zorn, U., Dallmann, I., Grosse, J., Kirchner, H., Poliwoda, H., Atzpodien, J.: Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother 9, 225 (1994).
87. von Hoegen, P., Zawatzky, R., Schirrmacher, V.: Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytotoxic T-cell activity via induction of Interferon alpha/beta. Cell Immunol 126, 80 (1990).
88. Ertel, C., Millar, N.S., Emmerson, P.T., Schirrmacher, V., von Hoegen, P.: Viral hemagglutinin augments peptide-specific T cell responses. Eur J Immunol 23, 2592 (1993).
89. Ten, R.M., Blank, V., Le Bail, O., Kourilsky, P., Israel, A.: Two factors IRF1 and KNF1/NF-kappa B, cooperate during induction of MHC class 1 gene expression by Interferon alpha, beta or Newcastle disease virus. C.R. Acad Sci III 316, 496 (1993).
90. Hou, S., Mo, X.T., Hyland, L., Doherty, P.C.: Host response to Sendai virus in mice lacking class II major histocompatibility complex glycoproteins. J Virol 69, 1429 (1995).
91. Umansky, V., Shatrov, V.A., Lehmann, V., Schirrmacher, V.: Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B. Int Immunol 8, 491 (1996).
92. Collins, P.L., Hightower, L.E.: Newcastle disease virus stimulates the cellular accumulation of stress (heat shock) mRNAs and proteins. J Virol 44, 703 (1982).
93. Edgington, S.M.: Therapeutic applications of heat shock proteins. Biotechnology 13, 1442 (1995)
94. Pardoll, D.M.: Cancer vaccines. Nat Med 4(5 Suppl.), 525 (1998)
95. Reichard, K.W., Lorence, R.M., Cascino, C.J., Peeples, M.E., Walter, R.J., Fernando, M.B., Reyes, H.M., Greager, J.A.: Newcastle disease virus selectively kills human tumor cells. J Surg Res 52, 448 (1992).
96. Bar-Eli, N., Giloh, H., Schlesinger, M., Zakay-Rones, Z.: Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. J Cancer Res Clin Oncol 122, 409 (1996).
97. Lorence, R.M., Katubig, B.B., Reichard, K.W., Phuangsab, A., Sassetti, M.D., Walter, R.J., Peeples, M.E.: Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 54, 6017 (1994).
98. Hock, H., Dorsch, M., Kunzendorf, U., Berla, K., Qin, Zh., Diamantstein, T., Blankenstein, T.: Vaccination with tumor cells genetically engineered to produce different cytokines: Effectivity not superior to a classical adjuvant. Cancer Res 53, 714 (1993).
99. Gu, X.G., Schmitt, M., Hiasa, A., Nagata, Y., Ikeda, H., Sasaki, Y., Akiyoshi, K., Sunamoto J., Nakamura, H., Kunbayashi, K., Shiku, H.: A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res 58, 3385 (1998).
100. Hariharan, K., Braslawsky, G., Barnett, R.S., Berquist, L.G., Huynh, T., Hanna, N., Black, A.: Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Im J Oncol 12, 1229 (1998).
101. McLaughlin, J.P., Schlom, J., Kantor, J.A., Greiner, J.W.: Improved immunotherapy of a recombinant carcinoembryonic antigen vaccine when given in combination with interleukin-2 Cancer Res 56 2361 (1996).
102. Kirchner, H.H., Anton, P., Atzpodien, J.: Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccine. World J Urol 13, 171 (1995).
103. Payvandi, F., Amrute, S., Fitzgerald-Bocarsaly, P.: Exogenous and endogenous IL-10 regulate IFN production by peripheral blood mononuclear cells in response to viral stimulation. J Immunol 160, 5861 (1998).
104. Mottonen, M., Isomaki, P., Saario, R., Toivanen, P., Punnonen, J., Lassila, O.: Interleukin-10 inhibits the capacity of synmovial macrophages to function as antigen-presenting cells. Br J Rheumat 37, 1207 (1998).
105. Schwartz, R., Momburg, F., Moldenhauer, G., Dorken, B., Schirrmacher, V.: Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-gamma. Int J Cancer 35, 245 (1985).
106. Lee, R.K., Spielman, J., Zhao, D.Y., Olsen, K.J., Podack, E.R.: Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 157, 1919 (1996).
107. O'Connell, J., O'Sullivan, G.C., Collins, K., Shanahan, F.: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184, 1075 (1996).
108. Hahne, M., Rimaldi, D., Schroter, M., Romero, P., Schreier, M., French, L.E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Carottini, J., Tachopp, J.: Melanoma cell expression of Fas(APO-1/CD95) ligand: implication for tumor immune escape. Science 274, 1363 (1996).
109. Strand, S., Hofmann, W.J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S.M., Stremmel, W., Krammer, P.H., Galle, P.R.: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nature Med 2, 1361 (1996).
110. Niehans, G.A., Brunner, T., Frizelle, S.P., Liston, J.C., Salerno, C.T., Knapp, D.J., Green, D.R., Kratzke, R.A.: Human lung carcinomas express Fas ligand. Cancer Res., 57, 1007 (1997).
111. Sinkovics, J.G.: Malignant lymphoma arising from natural killer cells: report of the first case in 1970 and newer developments in the FasL-→FasR system. Acta Microbiol Immunol Hung 44, 295 (1997)
112. + CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 161, 1220 (1998).
113. Sinkovics, J.G.: Viral oncolysates as human tumor vaccines. Intern Rev Immunol 7, 259 (1991)